Abstract:9‐amino‐8‐bromo‐3,4‐dihydroacridin‐1(2H)‐one (KY‐31) displayed relatively low toxicity and retained anti‐inflammatory activity with a higher selectivity index compared to 9‐aminacrine (9‐AA). It may exert its anti‐inflammatory effects through the nuclear receptor subfamily 4 group A member 1 (NR4A1)/Interleukin‐10 (IL‐10)/suppressors of cytokine signalling 3 (SOCS3) signaling pathway and inhibit the protein targets phosphodiesterase‐4 (PDE‐4) and p38 mitogen‐activated protein kinases (MAPK). These findings support further development and exploration of 9‐amino‐8‐bromo‐3,4‐dihydroacridin‐1(2H)‐one as a promising anti‐inflammatory compound for inflammatory conditions. 9‐aminacrine (9‐AA), an external antibacterial agent, possesses important bioactivities for the treatment of cancer, viruses, and prion diseases. Recent research has revealed that 9‐AA has anti‐inflammatory effects through the up‐regulation of nuclear receptor subfamily 4 group A member 1 (NR4A1), but it is highly cytotoxic. To mitigate its toxicity, three series of novel 9‐AA derivatives were synthesized. The toxicity of all compounds was assessed, and some of the less toxic compounds were tested for in vitro anti‐inflammatory activities, leading to the establishment of structure‐activity relationships. In particular, 9‐amino‐8‐bromo‐3,4‐dihydroacridin‐1(2H)‐one exhibited relatively low toxicity and retained anti‐inflammatory activity, with a higher selectivity index compared to 9‐AA (3.44 versus 0.68). Expression experiments of inflammatory mediators revealed that this compound not only inhibited the gene expression of pro‐inflammatory factors, but also promoted the gene expression of anti‐inflammatory factors. Preliminary mechanistic studies suggested that it exerted anti‐inflammatory effects through the NR4A1/Interleukin‐10 (IL‐10)/suppressors of cytokine signalling 3 (SOCS3) signaling pathway. Furthermore, molecular docking studies indicating that it may exhibit anti‐inflammatory activity by inhibiting the protein targets phosphodiesterase‐4 (PDE‐4) and p38 mitogen‐activated protein kinases (MAPK). Based on our data, 9‐amino‐8‐bromo‐3,4‐dihydroacridin‐1(2H)‐one with its low toxicity and anti‐inflammatory properties, holds promise for further development as an anti‐inflammatory agent.

Novel 12-membered non-antibiotic macrolides from erythromycin A; EM900 series as novel leads for anti-inflammatory and/or immunomodulatory agents

A novel 12-membered ring non-antibiotic macrolide EM982 attenuates cytokine production by inhibiting IKKβ and IκBα phosphorylation

Synthesis and antibacterial activity of novel 11-[3-[(arylcarbamoyl)oxy]propylamino]-11-deoxy-6-O-methyl-3-oxoerythromycin A 11-N,12-O-cyclic carbamate derivatives

Synthesis and antiproliferative activity of novel erythromycin derivatives

Total Synthesis, Stereochemical Assignment, and Biological Evaluation of Opantimycin A and Analogues Thereof

Total Synthesis, Structural Reassignment, and Biological Evaluation of the Anti-Inflammatory Macrolactone 13-Hydroxy-14-deoxyoxacyclododecindione

Synthesis and Antibacterial Activity of Erythromycin 9-Acylhydrazone Derivates

Somalactams A–D: Anti‐inflammatory Macrolide Lactams with Unique Ring Systems from an Arctic Actinomycete Strain

Paenimacrolidin, a Novel Macrolide Antibiotic from Paenibacillus Sp. F6‐B70 Active Against Methicillin‐resistant Staphylococcus Aureus

A new type of ketolide bearing an N-aryl-alkyl acetamide moiety at the C-9 iminoether: synthesis and structure-activity relationships

Synthesis and biological evaluation of new nicotinic acid derivatives as potential anti-inflammatory agents with enhanced gastric safety profile

Design, synthesis and anti-inflammatory evaluation of aloe-emodin derivatives as potential modulators of Akt, NF-κB and JNK signaling pathways

Synthesis and Antibacterial Evaluation of Novel Clarithromycin Derivatives with C-4″ Elongated Arylalkyl Groups Against Macrolide-Resistant Strains.

Design, Synthesis and Structure-activity Relationships of Novel Non-ketolides: 9-Oxime Clarithromycin Featured with Seven- to Thirteen-atom-length Diamine Linkers at 3-OH

From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials

Design, Synthesis, Biological Evaluation and Docking Study of A New Series of 9‐aminoacridine Derivatives as Anti‐inflammatory Agents

Synthesis of a novel series of diphenolic chromone derivatives as inhibitors of NO production in LPS-activated RAW264.7 macrophages.

Novel 2-Phenyl-4h-chromen Derivatives: Synthesis and Anti-Inflammatory Activity Evaluation in Vitro and in Vivo

Design, synthesis and molecular docking of novel D-ring substituted steroidal 4,5-dihydropyrazole thiazole derivatives that act as iNOS/COX-2 inhibitors with potent anti-inflammatory activity against LPS-induced RAW264.7 macrophage cells

Structure-Activity Relationships and Mechanism of Action of Macrolides Derived from Erythromycin as Antibacterial Agents

Scaffold Modifications in Erythromycin Macrolide Antibiotics. A Chemical Minireview